**

PLL Therapeutics Bolsters ALS Research with Appointment of Leading Neurologist Philippe Corcia to Scientific Board

[City, State] – [Date] – PLL Therapeutics, a biotechnology company focused on developing innovative therapies for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, today announced the appointment of renowned neurologist and ALS expert Professor Philippe Corcia to its Scientific Advisory Board. This strategic addition significantly strengthens PLL Therapeutics' commitment to accelerating the development of effective treatments for this devastating neurodegenerative disease. Professor Corcia's extensive experience and groundbreaking research in ALS will provide invaluable guidance as PLL Therapeutics advances its pipeline of promising therapeutic candidates.

Professor Corcia: A Leading Figure in ALS Research

Professor Corcia brings decades of experience in the field of neurology, with a particular focus on ALS research and clinical trials. He is widely recognized for his significant contributions to understanding the disease's pathophysiology, improving diagnostic techniques, and evaluating novel therapeutic strategies. His expertise spans several key areas crucial to ALS drug development, including:

• Clinical Trial Design and Execution: Professor Corcia has a proven track record of designing and leading successful clinical trials for ALS, ensuring rigorous methodologies and ethical considerations are prioritized. This experience is vital for navigating the complexities of ALS clinical development.
• Biomarker Discovery and Validation: His research has been instrumental in identifying and validating potential biomarkers for ALS, which can be used to monitor disease progression and assess the effectiveness of new therapies. This is crucial for accelerating the drug development process and improving patient outcomes.
• Translational Research: Professor Corcia has a deep understanding of translating preclinical research findings into clinical applications, bridging the gap between laboratory discoveries and patient benefit. This is critical for ensuring that promising therapies reach patients effectively.
• ALS Genetics and Pathogenesis: His research encompasses the genetic basis of ALS and the complex mechanisms that drive the disease's progression, leading to a comprehensive understanding of potential therapeutic targets.

PLL Therapeutics' Commitment to ALS Innovation

PLL Therapeutics is dedicated to developing innovative therapies targeting unmet medical needs in ALS. The company's pipeline includes several promising drug candidates currently undergoing preclinical and clinical development. The appointment of Professor Corcia represents a significant step forward in realizing the company's mission.

The company's strategic focus areas include:

• Targeting Neuroinflammation: PLL Therapeutics is investigating therapies that aim to reduce the harmful neuroinflammation characteristic of ALS. This approach addresses a key aspect of the disease's pathogenesis.
• Neuroprotection: The company is actively developing neuroprotective agents designed to safeguard vulnerable motor neurons from further damage and slow the progression of the disease.
• RNA-Based Therapies: PLL Therapeutics is exploring novel RNA-based therapeutic strategies that have the potential to address the underlying genetic causes of ALS. This area of research is considered highly promising for developing effective treatments.

The addition of Professor Corcia's expertise strengthens PLL Therapeutics' ability to advance its research in these key areas, accelerating the development of effective ALS treatments.

The Impact of Professor Corcia's Appointment

The appointment of Professor Corcia to the Scientific Advisory Board marks a significant milestone for PLL Therapeutics. His contribution will be vital in several key areas:

• Guiding Research Strategy: Professor Corcia's deep understanding of ALS will help guide the company's research direction, ensuring its resources are focused on the most promising therapeutic avenues.
• Mentoring Research Teams: He will provide valuable mentorship and guidance to PLL Therapeutics' research teams, fostering innovation and accelerating progress.
• Enhancing Clinical Development: His expertise in clinical trial design will be instrumental in ensuring that PLL Therapeutics' clinical trials are conducted efficiently and effectively, maximizing the chances of success.
• Strengthening Industry Collaboration: Professor Corcia's extensive network within the ALS research community will help strengthen PLL Therapeutics' collaborations with other leading institutions and researchers.

The Urgent Need for Effective ALS Treatments

ALS is a devastating neurodegenerative disease characterized by progressive loss of motor neurons, leading to muscle weakness, paralysis, and ultimately, death. There is currently no cure for ALS, and existing treatments only offer limited benefits. The need for effective new therapies is urgent, and PLL Therapeutics is committed to bringing hope to patients and their families.

Looking Ahead: A Brighter Future for ALS Patients

With the addition of Professor Philippe Corcia to its Scientific Advisory Board, PLL Therapeutics is well-positioned to make significant contributions to the fight against ALS. This appointment reflects the company’s unwavering dedication to innovation and its commitment to accelerating the development of life-changing treatments for this devastating disease. The collaborative efforts of leading researchers and innovative biotechnology companies offer a brighter future for ALS patients and their families, bringing renewed hope in the search for effective therapies and, ultimately, a cure. The progress made in understanding ALS pathogenesis, coupled with advancements in drug development, provide a significant reason for optimism. The work being done by PLL Therapeutics, guided by experts like Professor Corcia, signifies a critical step towards achieving this important goal. This exciting development in the ALS research landscape signals a positive outlook for the future of ALS treatment.